By Jacqueline Howard, CNN
Two House committees have launched an investigation into the approval and pricing of the Alzheimer’s disease drug aducanumab, made by the company Biogen and sold under the brand name Aduhelm.
The US Food and Drug Administration approved the drug earlier this month under its “accelerated approval” program, although an FDA advisory committee concluded last year that there was not enough evidence to support the effectiveness of the treatment.
Biogen announced in early June that the wholesale cost of treatment — which requires an infusion once every four weeks — is about $4,312 per infusion, making the annual cost about $56,000 for a high dose.